Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Valganciclovir in CMV Retinitis Patients with IV Complications
NCT00017784Phase 3Unknown
- Sponsor
- Roche
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of valganciclovir in cytomegalovirus retinitis, sponsored by Roche. Primary endpoint: Safety and Adverse Events. Status: unknown.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT00017784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017784.